Luca Idolazzi
Overview
Explore the profile of Luca Idolazzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
118
Citations
1526
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gisondi P, Bellinato F, Galeone C, Turati F, Idolazzi L, Zabotti A, et al.
Ann Rheum Dis
. 2025 Feb;
84(3):435-441.
PMID: 39919973
Objectives: To investigate the risk of psoriatic arthritis (PsA) in plaque psoriasis (PsO) patients receiving different classes of biologics. Methods: A retrospective observational study involving consecutive bionaïve PsO patients starting...
2.
Bixio R, Mastropaolo F, Nava F, Veliaj O, Fracassi E, Viapiana O, et al.
J Scleroderma Relat Disord
. 2024 Nov;
:23971983241285206.
PMID: 39544895
Introduction: Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis and vascular abnormalities, often leading to the development of digital ulcers (DUs). DUs are painful and debilitating, significantly...
3.
De Marco G, Marchesoni A, Manara M, Gisondi P, Idolazzi L, Ramonda R, et al.
Clin Exp Rheumatol
. 2024 Oct;
43(1):28-33.
PMID: 39480505
Objectives: The purpose of this study was to evaluate the performance of a dermatologist-filled-in 7-item questionnaire (called HERACLES) as a screening tool for psoriatic arthritis (PsA) in patients with psoriasis....
4.
Bixio R, Adami G, Bertoldo E, Giollo A, Morciano A, Bertelle D, et al.
Ther Adv Musculoskelet Dis
. 2022 Nov;
14:1759720X221137125.
PMID: 36439640
Background: Systemic sclerosis (SSc) is an autoimmune disease characterized by vasospasm and microvascular involvement. Iloprost (ILO), a prostaglandin analogous, is used for the treatment of SSc-related Raynaud's phenomenon and digital...
5.
Bellinato F, Gisondi P, Filippucci E, Tozzi F, Fassio A, Adami G, et al.
Arch Dermatol Res
. 2022 Nov;
315(3):601.
PMID: 36434322
No abstract available.
6.
Bellinato F, Gisondi P, Filippucci E, Tozzi F, Fassio A, Adami G, et al.
Arch Dermatol Res
. 2022 Oct;
315(3):593-600.
PMID: 36271200
Ultrasonography (US) of the nail is raising interest in the last years and its feasibility, quickness and amount of descriptive data may provide valuable information. Different authors presented several scanning...
7.
Gremese E, Ciccia F, Selmi C, Cuomo G, Foti R, Matucci-Cerinic M, et al.
Clin Exp Rheumatol
. 2022 Oct;
41(3):735-743.
PMID: 36226614
Objectives: To compare real-world persistence, effectiveness and tolerability of ustekinumab versus TNF inhibitors (TNFi) in psoriatic arthritis (PsA). Methods: One-year data from Italian subjects enrolled in the PsABio study (PsA...
8.
Trentadue M, Sozzi C, Idolazzi L, Lazzarini G, Murano R, Gatti D, et al.
Radiol Bras
. 2022 Aug;
55(4):216-224.
PMID: 35983340
Objective: To promote advanced research using magnetic resonance imaging (MRI) in the diagnosis of and screening for osteoporosis by looking for correlations among the T-scores measured by dual-energy X-ray absorptiometry...
9.
Bellinato F, Adami G, Vaienti S, Benini C, Gatti D, Idolazzi L, et al.
JAMA Dermatol
. 2022 Feb;
158(4):375-381.
PMID: 35171203
Importance: Psoriasis is a chronic inflammatory disease with a relapsing-remitting course. Selected environmental factors such as infections, stressful life events, or drugs may trigger disease flares. Whether air pollution could...
10.
Zabotti A, De Lucia O, Sakellariou G, Batticciotto A, Cincinelli G, Giovannini I, et al.
Rheumatol Ther
. 2021 Oct;
8(4):1519-1534.
PMID: 34596875
Background: Agreement on how to identify psoriasis (PsO) patients at risk of developing psoriatic arthritis (PsA) is lacking. Objective: To identify predictors, risk factors and incidence rate (IR) of PsA...